Clinical Research Directory

Inclusion Criteria: * Men and premenopausal women, 18-49 years, with obesity defined as BMI ≥ 30 kg/m2 * Upon the initiation of Semaglutide (within the first 1-4 weeks) for medical weight management, for clinical purposes, as advised by the primary physician * Able to commit for a 6-month trial visits Exclusion Criteria: * Pregnant women * Patients who are taking or have taken other weight reducing drug therapies in the previous 6 months * Patients who have undergone metabolic weight loss surgery * Patients known to have diabetes (HbA1c ≥6.5% at screening) * Patients with uncontrolled hypertension * Patients with uncontrolled cardiac disease, pulmonary, renal or liver diseases, active cancer or psychiatric diseases * Patients with excessive alcohol intake, defined as ≥ 2 glasses per day * Patients known to have uncontrolled/ untreated thyroid disorders. * Patients with cushing disease or polycystic ovaries, and those with neuro-endocrine or drug induced obesity (such as anti-psychotic, steroids, hormonal therapy): Such patients are resistant to weight loss, and they need treatment of their primary disease and/or cessation of the culprit medication to lose weight * Patients with untreated gout * Patients who have undergone bariatric surgery